Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis
Hepatology Research2020Vol. 51(2), pp. 201–215
Citations Over TimeTop 10% of 2020 papers
Makoto Chuma, Haruki Uojima, Atsushi Hiraoka, Satoshi Kobayashi, Hidenori Toyoda, Toshifumi Tada, Hisashi Hidaka, Shogo Iwabuchi, Kazushi Numata, Ei Itobayashi, Norio Itokawa, Kazuya Kariyama, Hideko Ohama, Nobuhiro Hattori, Shunji Hirose, Hiroshi Shibata, Joji Tani, Michitaka Imai, Kazuto Tajiri, Satoshi Moriya, Naohisa Wada, Shuitirou Iwasaki, Taito Fukushima, Makoto Ueno, Satoshi Yasuda, Masanori Atsukawa, Kazuhiro Nouso, Shinya Fukunishi, Tsunamasa Watanabe, Toru Ishikawa, Shinichiro Nakamura, Manabu Morimoto, Tatehiro Kagawa, Michiie Sakamoto, Takashi Kumada, Shin Maeda
Abstract
Lenvatinib treatment offers a benefit in highly advanced HCC (tm50%LO or VP4) patients with good liver function or nodular-type tumor. The various characteristics identified in this study might be useful as indicators of lenvatinib treatment in highly advanced HCC with tm50%LO or VP4, which are considered very refractory cancers.
Related Papers
- → Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma(2021)38 cited
- → Sequential Analysis of Neutrophil-to-lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib(2020)33 cited
- → Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients(2022)16 cited
- → Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma(2020)12 cited
- → Unresectable hepatocellular carcinoma: prospects for drug therapy with lenvatinib(2022)1 cited